Picture of Mauna Kea Technologies SA logo

ALMKT — Mauna Kea Technologies SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Brief: Mauna Kea Technologies Announces Positive Results On Needle-Based Endomicroscopy For Clinical Management Of Pancreatic Cystic Lesions

Jan 8 (Reuters) - Mauna Kea Technologies SAS  MKEA.PA :
    * MAUNA KEA TECHNOLOGIES ANNOUNCES PUBLICATION OF POSITIVE
RESULTS
ON NEEDLE-BASED ENDOMICROSCOPY FOR THE CLINICAL MANAGEMENT OF
PANCREATIC CYSTIC LESIONS
    * CLINICAL TRIAL PUBLISHED IN PEER-REVIEWED JOURNAL
DEMONSTRATES
DIAGNOSTIC YIELD FROM CELLVIZIO® SIGNIFICANTLY EXCEEDS STANDARD
OF CARE
    * USE OF CELLVIZIO DRIVES OVERALL CHANGE IN CLINICAL
MANAGEMENT -
INCLUDING NEED FOR CONTINUED SURVEILLANCE OR SURGERY - IN 42.3%
OF CASES
    * RESULTS OF THIS STUDY CLEARLY DEMONSTRATE THAT MFB AND
NCLE LEAD
TO SIGNIFICANT IMPROVEMENTS IN SPECIFIC PCL DIAGNOSIS, WHICH IN
TURN HAS MAJOR IMPACT IN CLINICAL MANAGEMENT
    * THIS STUDY FURTHER ENHANCES GROWING BODY OF EVIDENCE
    * SAYS BELIEVE EVIDENCE OF CHANGING PATIENT MANAGEMENT FOR
PANCREATIC CYSTS WILL HELP DRIVE ADOPTION IN U.S. GOING FORWARD

Source text for Eikon:  ID:nBw807Fcxa 
Further company coverage:  MKEA.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))

Recent news on Mauna Kea Technologies SA

See all news